Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2731 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.1612 | 0.2852 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.1612 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2685 | 0.9706 | 0.9706 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.1612 | 0.2852 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2731 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.2731 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.2685 | 0.9706 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.2685 | 0.9706 | 0.9604 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.1612 | 0.2852 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.2731 | 1 | 0.5 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2685 | 0.9706 | 0.9706 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2731 | 1 | 1 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.2731 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.1612 | 0.2852 | 0.5 |
Onchocerca volvulus | 0.2731 | 1 | 0.5 | |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.2685 | 0.9706 | 0.9706 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.2731 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 459.02 uM | Antipromastigote activity against Leishmania braziliensis MCAN/BR/98/R619 after 24 hrs by MTT assay | ChEMBL. | 24125880 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.